PT  - JOURNAL ARTICLE
AU  - MINORU HORIUCHI
AU  - TETSUYA OGURI
AU  - YUSUKE KAGAWA
AU  - KAZUKI SONE
AU  - SATOSHI FUKUDA
AU  - TAKEHIRO UEMURA
AU  - OSAMU TAKAKUWA
AU  - KEN MAENO
AU  - KENNSUKE FUKUMITSU
AU  - YOSHIHIRO KANEMITSU
AU  - TOMOKO TAJIRI
AU  - HIROTSUGU OHKUBO
AU  - MASAYA TAKEMURA
AU  - YUTAKA ITO
AU  - AKIO NIIMI
TI  - Differences in the Therapeutic Effect of Chemotherapy Regimens for Concurrent Chemoradiotherapy of Locally Advanced Non-small Cell Lung Cancer
AID  - 10.21873/anticanres.15569
DP  - 2022 Feb 01
TA  - Anticancer Research
PG  - 1073--1079
VI  - 42
IP  - 2
4099  - http://ar.iiarjournals.org/content/42/2/1073.short
4100  - http://ar.iiarjournals.org/content/42/2/1073.full
SO  - Anticancer Res2022 Feb 01; 42
AB  - Background/Aim: The optimal chemotherapy for concurrent chemoradiotherapy (cCRT) of lung cancer is still unclear. Patients and Methods: We investigated the therapeutic effect of different chemotherapy regimens for cCRT of lung cancer in 65 patients at our hospital. Results: Of the 65 patients, 53 were male and 12 female. The median age was 64 years and 58 participants had a smoking history. The histological type was adenocarcinoma in 34 cases, squamous cell carcinoma in 22 cases, and others in 9 cases. Induction therapy consisted of cisplatin plus vinorelbine (CDDP+VNR) in 50 cases, and weekly carboplatin plus paclitaxel (CBDCA+PTX) in 15 cases. In all patients, the overall response rate, disease control rate, median progression survival, and median overall survival were 78.5%, 95.4%, 337 days, and 1,037 days, respectively. The median progression-free survival was 337 days in total; it was significantly longer for CDDP+VNR than CBDCA+PTX. The median overall survival was 1,037 days in total; it tended to be slightly longer for CDDP+VNR than CBDCA+PTX. Conclusion: Different chemotherapy regimens for cCRT possibly have different therapeutic effects.